For the treatment of estrogen receptor (ER)-positive early breast cancer, 10 years of treatment with tamoxifen yields better outcomes than 5 years of treatment, according to an analysis from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.
A comparison of letrozole (Femara) with tamoxifen (Nolvadex) demonstrated that the former may be superior for the treatment of postmenopausal estrogen receptor (ER)-positive patients who have lobular carcinoma, according to a subanalysis of patients in the phase 3 BIG 1-98 trial. This subanalysis further showed that for the 2 histologic subtypes of breast cancer, luminal B tumors were more responsive to treatment than luminal A tumors.
Although many clinicians are already prescribing fulvestrant (Faslodex) at a dose of 500 mg, a phase 3 study presented at the meeting confirmed the superiority of this dose over 250 mg.
Results 1 - 3 of 3